Skip to main content

Levonorgestrel-Releasing Intrauterine System with or without Everolimus in Treating Patients with Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

Trial Status: Active

This randomized phase II trial studies how well levonorgestrel-releasing intrauterine system works when given alone or with everolimus in treating patients with atypical hyperplasia (a pre-cancerous growth of the lining of the uterus) or stage IA grade 1 endometrial cancer. The levonorgestrel-releasing intrauterine system is designed to prevent pregnancy by releasing a hormone called levonorgestrel, which is a type of progesterone. Progesterone is a common type of hormone that is used to prevent pregnancy and may prevent or slow tumor cell growth. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether the levonorgestrel-releasing intrauterine system works better with or without everolimus in treating patients with atypical hyperplasia or stage IA grade 1 endometrial cancer.

Inclusion Criteria

  • All patients with a diagnosis of complex atypical hyperplasia OR, grade 1 endometrioid OR focal grade 2 adenocarcinoma in predominately grade 1 disease endometrial carcinoma on endometrial biopsy or dilation and curettage (D & C) within three months of study enrollment
  • Patients with complex atypical hyperplasia OR grade 1 endometrioid adenocarcinoma with stable/persistent disease with LIUD already in place. LIUD must have been in place for at least 3 months
  • Prior progesterone treatment is ALLOWED, but a 28 day washout period is required before LIUD placement. If archival tissue is available from prior to any progesterone treatment, the washout period is not needed
  • Ability to comply with endometrial biopsies every 3 months
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2
  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
  • Platelets >= 100 x 10^9/L
  • Hemoglobin (Hb) > 9 g/dL
  • Total serum bilirubin =< 2.0 mg/dL
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
  • International normalized ratio (INR) =< 2; factor 10A drawn if patient on anticoagulant Eliquis
  • Serum creatinine =< 1.5 x ULN
  • Fasting serum cholesterol =< 300 mg/dL OR =< 7.75 mmol/L AND fasting triglycerides =< 2.5 x ULN; NOTE: in case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication
  • Signed informed consent obtained prior to any screening procedures

Exclusion Criteria

  • Patients with grade 2-3 endometrioid, uterine serous, clear cell, mucinous, squamous, transitional cell, sarcomas, or carcinosarcoma histology
  • Evidence of extrauterine spread of disease on imaging or during surgical evaluation
  • Patients who have prior therapy with everolimus or any other mammalian target of rapamycin (mTOR) inhibitor
  • Patients currently receiving anticancer therapies (including chemotherapy, radiation therapy, hormonal, or antibody-based therapy); prior treatment should have a washout period of 28 days or 4 1/2 half-lives (7 days), whichever is shorter
  • Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
  • Known intolerance or hypersensitivity to progesterone or its excipients
  • Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus (e.g., inability to take oral medication or a requirement for intravenous [IV] alimentation, prior surgical procedures affecting absorption, malabsorption syndrome, and active peptic ulcer disease) are excluded; subjects with ulcerative colitis, inflammatory bowel disease, or a partial or complete small bowel obstruction are also excluded, as are any patients who cannot swallow the capsule whole
  • Uncontrolled diabetes mellitus as defined by glycosylated hemoglobin (HbA1c) > 8% despite adequate therapy; patients with a known history of impaired fasting glucose or diabetes mellitus (DM) may be included, however blood glucose and antidiabetic treatment must be monitored closely throughout the trial and adjusted as necessary
  • Patients who have any severe and/or uncontrolled medical conditions such as: a) unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction =< 6 months prior to start of everolimus, serious uncontrolled cardiac arrhythmia, or any other clinically significant cardiac disease; b) symptomatic congestive heart failure of New York Heart Association class III or IV; c) active (acute or chronic) or uncontrolled severe infection (not responding to antibiotics), liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis (i.e. quantifiable hepatitis B virus-deoxyribonucleic acid [HBV-DNA] and/or positive hepatitis B surface antigen [HbsAg], quantifiable hepatitis C virus-ribonucleic acid [HCV-RNA]); d) known severely impaired lung function (spirometry and diffusing capacity of the lung for carbon monoxide [DLCO] 50% or less of normal and oxygen [O2] saturation 88% or less at rest on room air); e) active, bleeding diathesis
  • Chronic treatment with corticosteroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowed
  • Patients who have a known history of human immunodeficiency virus (HIV) seropositivity
  • Patients who have received live attenuated vaccines within 1 week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella and TY21a typhoid vaccines
  • Other malignancies within the past 3 years except for basal or squamous cell carcinoma of the skin
  • Active (acute or chronic) or uncontrolled severe infections (not responding to antibiotics), including acute pelvic inflammatory disease
  • Congenital or acquired uterine anomaly which distorts the uterine cavity
  • Genital actinomycosis
  • Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study
  • Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing
  • Women who are pregnant or nursing (lactating) women
  • Women of child-bearing potential (WOCBP), defined as women physiologically capable of becoming pregnant, must use one additional highly effective methods of contraception in addition to the LIUD during the study and 8 weeks after; acceptable effective contraception methods include combo of the following: a) barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository; b) total abstinence or; c) male/female sterilization; women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation > six weeks prior to randomization; in the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child-bearing potential
  • Women who are on contraindicated medications to everolimus must have confirmation from their physician that they may change or discontinue the medication if randomized to the LIUD + everolimus arm


North Colorado Medical Center
Status: ACTIVE
Contact: Robin A. Lacour
McKee Medical Center
Status: ACTIVE
Contact: Robin A. Lacour


Queen's Medical Center
Status: ACTIVE
Contact: Keith Y. Terada
Phone: 808-526-2477


Covenant HealthCare Mackinaw
Status: ACTIVE
Contact: Gregory P. Sutton

New Jersey

Cooper Hospital University Medical Center
Contact: David Philip Warshal
Phone: 855-632-2667
MD Anderson Cancer Center at Cooper-Voorhees
Status: ACTIVE
Contact: David Philip Warshal

New York

New Hyde Park
Northwell Health Physician Partners
Status: ACTIVE
Contact: Marina Frimer


OhioHealth Mansfield Hospital
Contact: Aine Emma Clements


Oklahoma City
University of Oklahoma Health Sciences Center
Status: ACTIVE
Contact: Laura L. Holman
Phone: 405-271-8787


MD Anderson in The Woodlands
Status: ACTIVE
Contact: Lauren Patterson Cobb
Phone: 713-745-8511
Lyndon Baines Johnson General Hospital
Status: ACTIVE
Contact: Michaela Onstad Grinsfelder
Phone: 713-745-7418
M D Anderson Cancer Center
Status: ACTIVE
Contact: Shannon Neville Westin
Phone: 713-794-4314
MD Anderson West Houston
Status: ACTIVE
Contact: Michael W. Bevers
Memorial Hermann Memorial City Medical Center
Status: ACTIVE
Contact: Nicole Dierschke Fleming
Phone: 713-792-3245
The Woman's Hospital of Texas
Status: ACTIVE
Contact: Michael W. Bevers
League City
MD Anderson League City
Status: ACTIVE
Contact: Behrouz Zand
Phone: 713-563-4367
Sugar Land
MD Anderson in Sugar Land
Status: ACTIVE
Contact: Nicole Dierschke Fleming
Phone: 713-792-3245


University of Virginia Cancer Center
Status: ACTIVE
Contact: Kari Lassen Ring


I. Estimate the efficacy of the levonorgestrel intrauterine device (LIUD) (levonorgestrel-releasing intrauterine system) alone to treat complex atypical hyperplasia or stage Ia grade 1 endometrioid endometrial carcinoma with response rate.

II. Estimate the efficacy of the LIUD in combination with everolimus to treat LIUD-refractory complex atypical hyperplasia or stage Ia grade 1 endometrioid endometrial carcinoma with response rate.


I. Document the toxicity profile of the levonorgestrel intrauterine device alone or in combination with everolimus using the National Institutes of Health-National Cancer Institute (NIH-NCI) Common Terminology Criteria for Adverse Events version (v) 4.0.

II. Estimate overall survival (OS) and event-free survival (EFS) of patients with complex atypical hyperplasia or stage Ia grade 1 endometrioid endometrial cancer treated with the levonorgestrel IUD alone or in combination with everolimus.

III. Estimate the response duration associated with the levonorgestrel IUD alone or in combination with everolimus in patients with complex atypical hyperplasia or stage Ia grade 1 endometrioid endometrial cancer.


I. Determine if response to therapy can be predicted based on the molecular profile of the tumor, including estrogen-induced genes and relevant pathway members, or by change in gene expression after therapy.


First Stage

* If D&C confirms EEC grade 1 or CAH-patient enrolled

* If the patient is found to have stable disease at 3 months continue on to the second stage of the study to be randomized.

* If the patient has a complete response at 3 months; EMB 3 months later to confirm complete response.

* Once complete response confirmed, patient Continues EMB every 6-12 months until disease progression per provider.

* If the patient has progressive disease at 3 months- OFF STUDY

Second Stage

* Patients with stable disease at and 3 month EMB, recurrent disease at a subsequent EMB, or entering protocol with outside IUD in place showing stable disease demonstrating progesterone resistance

LIUD Only Arm

* Visits every 3 months

* EMB at 6 months

* if regression/SD: continue on study

* EMB at 9 months and 1 year:

* Off study for PD or D&C at MD’s discretion

* SD at 1 year: off study

* CR at 1 year: SOC EMB 3 months later then Q6 months if confirmed CR

* If continuing on study: Q6mo EMB until progression, D&C, or pt./provider decision

LIUD+Everolimus Arm

* If progression at cycle 3, 6, 9:

* Discontinue everolimus, patient taken off study

* CR at cycle 9:

* EMB to confirm response at cycle 12

* If response confirmed –EMB every 6 cycles (6 months)

* Continue evaluations on each cycle day 1

* SD at cycle 9:

* Discontinue everolimus, come off study

Trial Phase Phase II

Trial Type Treatment

Lead Organization
M D Anderson Cancer Center

Principal Investigator
Shannon Neville Westin

  • Primary ID 2014-0944
  • Secondary IDs NCI-2015-00919
  • ID NCT02397083